Emricasan 是一种不可逆的泛半胱天冬酶抑制剂。它抑制 Zika 病毒诱导的Caspase-3活性增加，有保护神经作用。

Emricasan is an effective and irreversible pan-caspase inhibitor.

Emricasan (IDN-6556 or PF-03491390) is an inhibitor of activated caspases, and it has sub- to nanomolar activity in vitro. Emricasan has a neuroprotective activity for hNPCs but does not inhibit ZIKV replication.

Emricasan reduces liver injury but not metabolic derangement in NASH. It also ameliorates inflammation. In the murine NASH model, Emricasan can attenuate stellate cell activation and hepatic fibrogenesis.

Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.(Only for Reference)

254750-02-2

C26H27F4N3O7

569.51

恩利卡生;IDN-6556;PF 03491390

Ethanol:93 mg/mL (163.3 mM)
H2O:<1 mgml
DMSO:93 mg/mL (163.3 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years